文献速递儿童青少年精神精神分裂症与精神病性障碍心境障碍

英格兰儿童青少年抗精神病药处方趋势:基于2000-19年初级保健数据的队列研究

Trends in antipsychotic prescribing to children and adolescents in England: cohort study using 2000-19 primary care data.
PubMed 文献 · Lancet Psychiatry · 2023-01-10

首次处方最常见可能适应症为孤独症谱系障碍、非情感性精神病、焦虑障碍、注意缺陷多动障碍(ADHD)、抑郁和品行障碍。

核心结论

  • 20年间抗精神病药处方增加源于同一批个体重复处方累积与新处方增加共同作用。
  • 研究提示需持续监测抗精神病药使用趋势并关注长期安全性信息。

研究设计与样本

  • 基于英格兰初级保健数据库(CPRD Aurum)的队列研究。
  • 采用算法基于临床代码推断首次抗精神病药处方最可能适应症。
  • 使用joinpoint回归分析识别结局趋势变化。

临床怎么用

  • 临床应关注儿童青少年抗精神病药处方的持续增长趋势,尤其是非典型抗精神病药的广泛使用。
  • 处方时应明确适应症,常见适应症包括孤独症谱系障碍、非情感性精神病、焦虑障碍、ADHD、抑郁和品行障碍。
  • 需加强对长期使用抗精神病药儿童青少年的安全性监测。

局限性

  • CPRD处方数据未与适应症直接链接,适应症通过算法推断。
  • 数据未收集种族信息。
  • 研究未考察抗精神病药长期安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prescription of antipsychotics to children and adolescents has been increasing worldwide. We described up-to-date trends in antipsychotic prescribing and identified likely indications in a contemporary English cohort. METHODS: We used a large primary care database, the Clinical Practice Research Datalink (CPRD) Aurum database, and we included all children and adolescents aged 3-18 years in the database and registered in England between Jan 1, 2000, and Dec 31, 2019, excluding those whose gender was recorded as indeterminate. Participants were followed up until the earliest of Dec 31, 2019, June 30 of the year they turned 18 years, their death, when they transferred from the primary care practice, or when the practice left the database. Data were not collected on ethnicity. We recorded antipsychotic prescriptions using the date a prescription was issued. As CPRD prescriptions are not linked to indications, we developed an algorithm to ascertain the most likely indication associated with participants' first antipsychotic prescription using clinical codes. We reported prescribing trends as annual period prevalence and the rate of first antipsychotic prescription, and we used joinpoint regression analysis to identify changes in the outcome trend. We stratified prevalence estimates by age group, gender, and Index of Multiple Deprivation quintiles, we reported frequencies of likely indications associated with incident prescriptions, and we explored clinical preference for typical versus atypical antipsychotics within deprivation quintiles. FINDINGS: Between Jan 1, 2000, and Dec 31, 2019, we included 7 216 791 children and adolescents, of whom 3 480 730 (48·2%) were girls and 3 736 061 (51·8%) were boys, with a mean age at the start of follow-up of 7·3 years (SD 4·9; range 3-18). Median follow-up was 4·1 years (IQR 1·5-8·5). 19 496 (0·3%) individuals received 243 529 antipsychotic prescriptions over follow-up, including 225 710 (92·7%) atypical and 17 819 (7·3%) typical antipsychotic prescriptions. The annual period prevalence of antipsychotic prescriptions rose from 0·057% (95% CI 0·052-0·063%) in 2000 to 0·105% (0·100-0·111%) in 2019. From joinpoint analyses, the period prevalence of all antipsychotic prescriptions increased by an average of 3·3% per year (2·2-4·9%) and the rate of first prescriptions increased by 2·2% per year (1·7-2·7%). The most likely indications of the first identified antipsychotic prescriptions were for autism spectrum disorder (2477 [12·7%]), non-affective psychosis (1669 [8·6%]), anxiety disorders (1466 [7·5%]), ADHD (1391 [7·1%]), depression (1256 [6·4%]), and conduct disorders (1181 [6·1%]). INTERPRETATION: The observed increase in antipsychotic prescriptions over 20 years results from the accumulation of repeated prescriptions to the same individuals combined with an increase in new prescriptions. These findings highlight the need for continued monitoring of trends in antipsychotic use and, although this was not examined in this paper, the findings highlights the need for better information about long-term antipsychotic safety. FUNDING: None.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Radojčić MR, Pierce M, Hope H, et al. Trends in antipsychotic prescribing to children and adolescents in England: cohort study using 2000-19 primary care data. Lancet Psychiatry. 2023. PMID: 36638816. doi:10.1016/S2215-0366(22)00404-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。